CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review.
Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
癌症给医学科学带来重大挑战,推动人们探索创新且高效的治疗策略。嵌合抗原受体(CAR)T 细胞疗法是癌症治疗的一项革命性突破,通过定制患者免疫细胞来对抗癌症。该疗法尤其成功地治疗血液系统恶性肿瘤,取得前所未有的疗效,并有望实现持久疾病控制。随着研究不断推进以克服现有挑战,CAR-T 有望成为抗癌的重要工具。持续改进旨在提高疗效、缩短治疗所需时间并降低成本;整合人工智能(AI)和物联网(IoT)技术后,或可使 CAR-T 更精准地适配个体患者并简化治疗流程,从而提高疗效、减轻不良反应并加速 CAR-T 疗法整体发展。
Cancer poses a formidable challenge in the field of medical science, prompting the exploration of innovative and efficient treatment strategies. One revolutionary breakthrough in cancer therapy is Chimeric Antigen Receptor (CAR) T-cell therapy, an avant-garde method involving the customization of a patient's immune cells to combat cancer. Particularly successful in addressing blood cancers, CAR T-cell therapy introduces an unprecedented level of effectiveness, offering the prospect of sustained disease management.
As ongoing research advances to overcome current challenges, CAR T-cell therapy stands poised to become an essential tool in the fight against cancer. Ongoing enhancements aim to improve its effectiveness and reduce time and cost, with the integration of Artificial Intelligence (AI) and Internet of Things (IoT) technologies.
The synergy of AI and IoT could enable more precise tailoring of CAR T-cell therapy to individual patients, streamlining the therapeutic process. This holds the potential to elevate treatment efficacy, mitigate adverse effects, and expedite the overall progress of CAR T-cell therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。